Osang Healthcare Co.,Ltd
Financials
Valuation Metrics
Osang Healthcare Co.,Ltd's Market Cap is ₩738B. At end of 2025 it was ₩1694B. Ranked #1407 of 2,410 in KR market (top 58%), #794 of 1,631 on KOSDAQ (top 49%), #52 of 94 in Health Care Equipment & Services (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.84B KRW | KR#1,407/2,410 Sec#52/94 |
| Revenue | 96.48B KRW | KR#1,436/2,410 Sec#40/94 |
| Net Income | -8.48B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 341.88B KRW | KR#967/2,410 Sec#19/94 |
| Net Assets | 279.58B KRW | KR#749/2,410 Sec#16/94 |
| Employees | 343 | KR#697/2,410 Sec#17/94 |
| Value | ||
| P/B | 0.26x | KR#304/2,410 Sec#3/94 |
| P/S | 0.77x | KR#1,277/2,410 Sec#20/94 |
| FCF Yield | -13.38% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | -3.03% | KR#1,720/2,410 Sec#58/94 |
| ROA | -2.48% | KR#1,788/2,410 Sec#60/94 |
| Op. Margin | -21.27% | KR#2,123/2,410 Sec#70/94 |
| Revenue Growth | -15.35% | KR#2,038/2,410 Sec#84/94 |
| Earnings Growth | -224.61% | KR#1,244/2,410 Sec#44/94 |
| Financial Health | ||
| Debt Ratio | 22.28% | KR#421/2,410 Sec#24/94 |
| Total Debt | 43.42B KRW | KR#1,055/2,410 Sec#26/94 |
| FCF | -9.88B KRW | KR#1,698/2,410 Sec#61/94 |
| Cash | 17.14B KRW | KR#1,341/2,410 Sec#37/94 |
| Current Ratio | 2.37x | KR#724/2,410 Sec#41/94 |
| Dividend | ||
| Div. Yield | 3.85% | KR#504/2,410 Sec#6/94 |
| Div. Growth | -60.00% | KR—/2,410 Sec—/94 |
| Performance | ||
| 1Y Return | -60.06% | KR#2,163/2,410 Sec#83/94 |
| 1M Return | -19.37% | KR#1,946/2,410 Sec#85/94 |
| From 52W High | -64.66% | KR#1,855/2,410 Sec#67/94 |
| 1Y MDD | -63.25% | KR#1,614/2,410 Sec#57/94 |
| Trading | ||
| Volume | 7,971 shares | KR#1,634/2,410 Sec#68/94 |
| Trading Value | 41.4M KRW | KR#1,551/2,410 Sec#67/94 |
| Foreign Own. | 1.12% | KR#1,980/2,410 Sec#72/94 |
| Per Share | ||
| EPS | -592 KRW | KR—/2,410 Sec—/94 |
| BPS | 19,538 KRW | KR#546/2,410 Sec#7/94 |
Company Info
Established in 1996, Osang Healthcare develops, produces, and sells biochemical, immunoassay, and molecular diagnostic products in the in-vitro diagnostics field, and was listed on KOSDAQ in 2024. With the new consolidation of OSANG COSMETIC LTDA, a Brazilian cosmetic distribution company, in 2025, the company now holds three subsidiaries. Its product portfolio includes self-blood glucose meters and POCT HbA1c meters for biochemical diagnostics; SelexOn and COVID-19 self-test kits for immunoassay diagnostics; and PCR-based Genefinder products for molecular diagnostics. Osang Healthcare is headquartered in Anyang-si, Gyeonggi-do.